{"filings":[{"id":91523,"accession_number":"0001437749-26-015198","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Accuray Q3 revenue down 7% to $104.8M; net loss $11.8M; withdraws FY2026 guidance","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.8M ($0.09 per share) vs $1.3M loss YoY; Adjusted EBITDA $3.8M vs $6.0M.","Product revenue fell 13% to $49.7M; service revenue down 1% to $55.1M.","Gross margin 24.1% vs 27.9% YoY; operating expenses include $6.5M restructuring charges.","Order backlog $356.2M, down 21% YoY; gross product orders $48.5M vs $71.2M.","Withdrew FY2026 guidance due to Middle East geopolitical uncertainty impacting shipments; transformation plan delivered $10M in cost savings ahead of $12M target."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":301028000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91522,"accession_number":"0001437749-26-013543","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Accuray COO Leonel Peralta departs effective April 26, 2026; no disagreement cited","event_type":"leadership","confidence":"high","bullets":["Leonel Peralta, SVP and Chief Operations Officer, resigned effective April 26, 2026.","Departure not due to any disagreement with Accuray or its board on operations, policies, or practices.","No successor has been named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91521,"accession_number":"0001437749-26-011547","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Accuray amends Dedication Capital consulting pact; cuts fees 50%, vests 916K shares immediately","event_type":"other_material","confidence":"high","bullets":["Cash compensation reduced 50%: Base fee $175K for Apr–Oct 2026, FY2026 incentive min $132.8K, Sep Q min $54.7K.","916,336 shares of Initial Restricted Shares (354,609 under 2016 plan, 561,727 under 2026) vested immediately as of Apr 1, 2026.","333,004 remaining Initial Restricted Shares to vest on Oct 31, 2026; PSAs still subject to stock price target.","Company expects at least $362,500 in cash savings from the amendment.","Consulting Agreement end date extended to October 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91520,"accession_number":"0001437749-26-011313","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Accuray appoints Paul Miele as SVP and Chief Commercial Officer","event_type":"leadership","confidence":"high","bullets":["Paul Miele appointed Chief Commercial Officer effective April 6, 2026.","Miele joins from Johnson & Johnson MedTech where he led the MONARCH robotic platform.","He will lead global commercialization strategy including sales, marketing, and pricing.","CEO Steve La Neve cites Miele's track record in driving transformation and sales growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101664,"accession_number":"0001437749-26-009046","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Accuray CCO Sandeep Chalke to depart March 31; separation includes $459K lump sum, equity vesting","event_type":"leadership","confidence":"high","bullets":["Sandeep Chalke, SVP & Chief Commercial Officer, leaves Accuray effective March 31, 2026.","Separation agreement provides $459,000 lump sum (12 months base salary) and prorated FY2026 bonus.","78,125 RSU shares originally vesting May 31, 2026 accelerate; all later equity forfeited.","Chalke executed a general release of claims and agreed to 12-month cooperation and non-disparagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101663,"accession_number":"0001437749-26-004223","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Accuray posts Q2 FY2026 earnings presentation; no detailed figures in filing","event_type":"earnings","confidence":"low","bullets":["Posted investor presentation for fiscal 2026 second quarter earnings call on Feb 17, 2026.","Presentation available on Accuray's IR website; no financial data provided in the 8-K or exhibit.","Ticker: ARAY; presentation includes forward-looking statements and summary information."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":196183000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101662,"accession_number":"0001437749-26-003515","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Accuray non-reliance on FY2025 and Q1 FY2026 financials over RPO footnote errors; no P&L impact","event_type":"other_material","confidence":"high","bullets":["Audit committee concluded audited FY2025 10-K and interim 10-Qs for FY2025 and Q1 FY2026 should no longer be relied upon due to RPO disclosure errors.","Errors isolated to the RPO footnote; no impact on balance sheets, income statements, or cash flows.","Material weaknesses identified in internal controls over financial reporting and disclosure controls; remediation plan underway.","Amended filings (10-K/A, 10-Q/A) to be filed; Q2 report expected within Rule 12b-25 extension period.","Errors caused by incorrect inclusion of open system/upgrade sales orders as RPO; methodology is being reassessed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101661,"accession_number":"0001437749-26-003367","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Accuray receives Nasdaq deficiency notice for bid price below $1; 180-day cure period","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on Feb 2, 2026 for non-compliance with $1 minimum bid price rule.","Has 180-day compliance period until Aug 3, 2026 to regain compliance by closing bid >= $1 for 10 consecutive days.","May be eligible for second 180-day period by transferring to Nasdaq Capital Market if not cured initially.","Common stock continues trading under symbol ARAY while company evaluates options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101660,"accession_number":"0001437749-26-002976","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Accuray Q2 net loss $0.11 per share; revenue down 12%; launches $25M transformation plan","event_type":"earnings","confidence":"high","bullets":["Total net revenue $102.2M, down 12% YoY; product revenue fell 26% to $45.0M, service revenue up 4% to $57.2M.","Net loss $13.8M ($0.11 diluted EPS) vs prior-year net income $2.5M ($0.02 EPS); adjusted EBITDA negative $1.9M.","CEO Steve La Neve announced transformational plan targeting ~$25M annualized operating profit improvement, including ~15% global workforce reduction.","Q2 restructuring charges $6.1M; ~$13M total restructuring charges expected for FY2026.","Updated FY2026 guidance: revenue $440-450M, adjusted EBITDA $22-25M; backlog $383.3M down 17% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":196183000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101659,"accession_number":"0001193125-26-016769","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Accuray CCO Sandeep Chalke resigns effective March 31, 2026","event_type":"leadership","confidence":"high","bullets":["Sandeep Chalke, SVP & Chief Commercial Officer, will resign effective March 31, 2026.","Resignation is voluntary and not due to any disagreement with Accuray or its Board.","No successor has been named; Chalke will serve through the effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117995,"accession_number":"0001437749-25-039074","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Accuray director Byron Scott to retire from board effective Dec 31, 2025","event_type":"leadership","confidence":"high","bullets":["Byron C. Scott, Class II director, informed board of retirement effective Dec 31, 2025.","Departure not due to any disagreement with company or its operations, policies, or practices.","Scott will resign from all board committees as of his retirement date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117994,"accession_number":"0001193125-25-319896","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["1.01","2.05","3.02","7.01","9.01"],"status":"ready","headline":"Accuray announces transformation plan; cuts 15% workforce, expects $25M annualized profit improvement","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~15% global headcount; total restructuring charges estimated at ~$11M, mostly cash.","Expects annualized operating profit improvement of ~$25M; ~$12M to be realized in FY2026.","Amends loan agreement: removes leverage condition for DDTL, reduces DDTL to $18.25M, delays covenant testing to Q4 FY2026.","Issues warrants for up to ~7M shares to lenders: exercise prices $1.50, $1.25, $0.01; additional warrants tied to DDTL draw.","Also pays $1.9M additional premiums and reduces revolver availability by $5M through Dec 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117993,"accession_number":"0001193125-25-288077","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Accuray shareholders approve 2026 equity plan, elect directors, ratify auditor","event_type":"other_material","confidence":"high","bullets":["Approval of 2026 Equity Incentive Plan authorizes up to 3,896,000 new shares plus rollover from prior plan.","All three Class I director nominees (Le Grand, Whitters, Galbato) elected with substantial support.","Advisory vote on executive compensation passed with ~87% of votes cast in favor.","Grant Thornton LLP ratified as independent auditor for FY2026 with 86.6M shares in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117992,"accession_number":"0001193125-25-266940","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Accuray Q1 revenue down 7%, net loss widens to $21.7M; CEO replaced, restructuring initiated","event_type":"earnings","confidence":"high","bullets":["Revenue $93.9M (-7% YoY); product revenue $37.2M (-23%); service revenue $56.8M (+7%).","Net loss $21.7M ($0.18/sh) vs loss $4.0M ($0.04) prior year; Adj. EBITDA loss $4.1M.","Appointed Steve La Neve as CEO, succeeding Suzanne Winter retiring; Steven F. Mayer as Transformation Board Sponsor.","Restructuring charges of $2.8M ($1.5M severance, $1.3M consulting) recorded in Q1.","FY2026 guidance reaffirmed: revenue $471M-$485M, Adj. EBITDA $31M-$35M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":93942000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117991,"accession_number":"0001193125-25-243143","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["1.01","2.02","5.02","9.01"],"status":"ready","headline":"Accuray appoints Steve La Neve as CEO; prelim Q1 rev $92.5-94M, adj EBITDA ~($4M)","event_type":"leadership","confidence":"high","bullets":["Steve La Neve appointed President & CEO effective Oct 20, 2025; succeeds Suzanne Winter who retired.","Steven F. Mayer named Transformation Board Sponsor under one-year consulting agreement with $600K base fee plus equity.","Preliminary Q1 FY2026 revenue $92.5-94M (product rev below expectations in EIMEA and China).","Preliminary Q1 adjusted EBITDA approximately ($4M) due to geographic mix and joint-venture accounting.","Transformation plan targets high single-digit adjusted EBITDA margin run-rate within 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134452,"accession_number":"0001193125-25-209044","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Accuray SVP, Chief Legal Officer Jesse Chew departs; consulting agreement through Dec 2025 at $20K/month","event_type":"leadership","confidence":"high","bullets":["Jesse Chew ceased employment as SVP, Chief Legal Officer and Corporate Secretary on Sept 19, 2025.","Consulting agreement runs Sept 19 to Dec 31, 2025; retainer $20,000/month plus continued equity vesting.","Services include transition support for CEO/CHRO/VP AGC, stockholder meeting prep, and contracts system implementation.","Consulting does not include legal advice; Chew must avoid competitors and get CEO approval for other radiation oncology work."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134451,"accession_number":"0001193125-25-186407","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Accuray director Kill not standing for re-election; Chief Legal Officer Chew to resign Sept 19","event_type":"leadership","confidence":"high","bullets":["Robert C. Kill, Class I director, will not stand for re-election at November 2025 annual meeting; continues until then.","Jesse Chew steps down as SVP, Chief Legal Officer and Corporate Secretary effective Sept 19, 2025.","Chew will consult through Dec 31, 2025 under terms to be agreed upon.","Both departures stated as not due to any disagreement with the company or board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134450,"accession_number":"0001193125-25-179806","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Accuray Q4 revenue $127.5M (-5% YoY); full year net loss narrows to $1.6M","event_type":"earnings","confidence":"medium","bullets":["Q4 revenue $127.5M, down 5% YoY; product revenue $70.7M (-11%), service revenue $56.8M (+4%).","Q4 net income $1.1M ($0.01 EPS) vs $3.4M ($0.03 EPS) prior year; adjusted EBITDA $9.4M vs $10.1M.","FY2025 revenue $458.5M (+3% YoY); net loss $1.6M vs $15.5M; adjusted EBITDA $28.3M vs $19.7M.","Backlog $427M, down 12.4% from FY2024 end; cash $58M, down $20.8M from Q3; debt refinancing completed.","FY2026 guidance mentioned but specific numbers not provided in the filing snippet."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":458505000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151292,"accession_number":"0000950103-25-007090","cik":1138723,"company_name":"ACCURAY INC","ticker":"ARAY","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Accuray refinances debt: $150M term loan from TCW, exchanges $82M notes for stock & cash","event_type":"debt","confidence":"high","bullets":["Exchanged ~$82M of 3.75% convertible notes for 8.88M shares and ~$68.6M cash; $18M of notes remain outstanding.","New $150M term loan, $20M delayed draw, $20M revolver with TCW; matures June 2030; interest SOFR+8.5% or base+7.5%.","Issued 17.2M Premium Warrants ($1.68 strike, 6-month lockout) and 6.25M Penny Warrants ($0.01 strike) to lenders.","Appointed Steven F. Mayer (TCW designee) to board; TCW also gets two non-voting observer seats.","Proceeds used to fully repay existing SVB credit facility and fund note exchange; existing agreement terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}